Scienture partners with distributor to sell REZENOPY naloxone spray to 2,000 US opioid treatment clinics
Bitget2026/09/22 12:15- Scienture Holdings entered an exclusive sales, marketing, distribution deal for REZENOPY naloxone spray with a partner focused on addiction treatment centers.
- Deal creates a dedicated channel across about 2,000 U.S. opioid treatment program clinics and other addiction treatment networks.
- Scienture continues selling REZENOPY outside this segment through wholesalers, GPOs, other distributors, institutional customers.
- IQVIA data for MAT July 2026 shows the U.S. naloxone market at about USD 140 million annual sales across 9,800,000 units.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lighter falls 11% after Bitwise’s LIT ETP launch – But there’s a catch!
To fit more HBM into chips, Nvidia accelerates advancement of glass substrate technology
German equipment manufacturer SCHMID has disclosed that it is collaborating with core firms in the supply chains of Intel, Nvidia, and AMD to develop glass substrate production equipment. Glass substrates are expected to replace silicon interposers, enhancing packaging density and data transmission capacity, and allowing for the integration of more HBMs. However, obstacles remain in the TGV metallization process, end-customer certification has not yet been completed, and large-scale commercialization will still take time.
Soma Gold Appoints New President
Crypto prices
More
